TCEPX
Price
$40.09
Change
-$0.10 (-0.25%)
Updated
Sep 20 closing price
VFFSX
Price
$279.76
Change
-$0.55 (-0.20%)
Updated
Sep 20 closing price
Ad is loading...

TCEPX vs VFFSX

Header iconTCEPX vs VFFSX Comparison
Open Charts TCEPX vs VFFSXBanner chart's image
Nuveen Equity Index Premier
Price$40.09
Change-$0.10 (-0.25%)
VolumeN/A
CapitalizationN/A
Vanguard 500 Index Institutional Select
Price$279.76
Change-$0.55 (-0.20%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
TCEPX vs VFFSX Comparison Chart
Loading...
VS
TCEPX vs. VFFSX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TCEPX is a Buy and VFFSX is a Buy.

FUNDAMENTALS
Fundamentals
VFFSX has more cash in the bank: 1.24T vs. TCEPX (48B). VFFSX pays higher dividends than TCEPX: VFFSX (1.33) vs TCEPX (1.18). TCEPX was incepted earlier than VFFSX: TCEPX (15 years) vs VFFSX (8 years). TCEPX is a more actively managed with annual turnover of: 7.00 vs. VFFSX (2.00). TCEPX has a lower initial minimum investment than VFFSX: TCEPX (0) vs VFFSX (5000000000). TCEPX (27.38) and VFFSX (26.47) have marching annual gain over last year. TCEPX (90.37) and VFFSX (87.72) have equivalent 5 years return.
TCEPXVFFSXTCEPX / VFFSX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence15 years8 years-
Gain YTD17.55418.20996%
Front LoadN/AN/A-
Min. Initial Investment05000000000-
Min. Initial Investment IRAN/AN/A-
Net Assets48B1.24T4%
Annual Yield % from dividends1.181.3389%
Returns for 1 year27.3826.47103%
Returns for 3 years23.6426.8288%
Returns for 5 years90.3787.72103%
Returns for 10 years173.77N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FRZA0.320.03
+12.01%
Forza X1
EVER22.26-0.02
-0.09%
EverQuote
RPRX28.21-0.03
-0.11%
Royalty Pharma plc
ATMU35.61-0.26
-0.72%
Atmus Filtration Technologies
OTLK5.93-0.11
-1.82%
Outlook Therapeutics